Economic assessment
Subtitle: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis
By: [A. Maetzel, M.D. Krahn, G. Naglie]
Contributors: Boucher, Michel, B Pharm; Brady, Bruce.; Krahn, M. D.; Naglie, Gary.; Canadian Coordinating Office for Health Technology Assessment.
Series: Technology overview -- issue 6.; Technology overview (Ottawa, Ont. : 1998) -- issue 6.
Publisher: Canadian Coordinating Office for Health Technology Assessment
Published: 2002
Place of publication: Ottawa, Ont
Language: eng
Number of pages: 15
Subjects: Celecoxib -- Therapeutic use -- Cost effectiveness.; Cyclooxygenase 2 -- Inhibitors -- Cost effectiveness.; Nonsteroidal anti-inflammatory agents -- Cost effectiveness.; Osteoarthritis -- Chemotherapy -- Cost effectiveness.; Rheumatoid arthritis -- Chemotherapy -- Cost effectiveness.; Rofecoxib -- Therapeutic use -- Cost effectiveness.
Notes: This overview is based on the technology report no. 23 entitled Cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis by A. Maetzel, M.D. Krahn and G. Naglie.--Cf. t. p.

"Bruce Brady and Michel Boucher (CCOHTA) are acknowledged for their significant contribution in the preparation of this overview".

At head of title: The Canadian Coordinating Office for Health Technology Assessment.

"February 2002".

Includes bibliographical references.